Celsion Corporation (CLSN)
| Market Cap | 161.10M |
| Revenue (ttm) | 500,000 |
| Net Income (ttm) | -21.57M |
| Shares Out | 34.11M |
| EPS (ttm) | -0.75 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | February 25 |
| Last Price | $2.20 |
| Previous Close | $2.26 |
| Change ($) | -0.06 |
| Change (%) | -2.65% |
| Day's Open | 2.44 |
| Day's Range | 2.11 - 2.47 |
| Day's Volume | 14,295,613 |
| 52-Week Range | 0.43 - 6.50 |
Celsion Corporation (NASDAQ: CLSN) reports interim observations and provides an update on its Phase 1/2 OVATION 2 study with GEN-1 in newly diagnosed patients with stage 3/4 ovarian cancer. GE...
Of 27 patients who completed interval debulking surgery, 80% of those treated with GEN-1 had an R0 resection compared with 58% of control patients, a 38% improvement
Non-Dilutive Funding Strengthens Balance Sheet; Extends Current Operating Runway to Over Three Years
Celsion (CLSN) stock was on the rise Monday after announcing fast-track approval from the U.S. Food and Drug Administration. The post CLSN Stock: Why Biotech Celsion Is Soaring Today appeared ...
Celsion's Commitment to Promoting Immune System Solutions to Fight Life-Threatening Diseases Granted an Accelerated Development Pathway
Board to provide guidance in developing the PLACCINE platform for the prevention and treatment of infectious agents, including SARS-CoV-2
Celsion (CLSN) stock is rising higher on Thursday after the release of a letter from chairman, president and CEO Michael Tardugno. The post CLSN Stock: Why Biotech Company Celsion Is Soaring T...
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
Lawrenceville, NJ, Jan. 26, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the closing of its previously announced registere...
LAWRENCEVILLE, NJ, Jan. 22, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institution...
Celsion Corporation (NASDAQ: CLSN) shares are trading at their highest level since early July after the company terminated a stock sale agreement. Celsion revealed in SEC filing it has notifie...
Celsion (CLSN) stock is soaring higher Thursday on heavy trading and InvestorPlace has all the details investors need to know. The post CLSN Stock Alert: 5 Things to Know About Celsion as Shar...
Shares of Celsion Corp. shot up 85.1% toward a six-month high in very active premarket trading Thursday, putting the on track to more than double in two days, after the cancer drug development...
LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--DEADLINE TODAY: The Schall Law Firm Announces it is Investigating Claims Against Celsion Corporation.
LOS ANGELES, Dec. 28, 2020 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Celsion Corporation ("Cels...
New York, New York--(Newsfile Corp. - December 28, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between...
NEW YORK, Dec. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between Novemb...
New York, New York--(Newsfile Corp. - December 24, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between...
NEW YORK, Dec. 24, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: ...
NEW YORK, Dec. 22, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 a...
New York, New York--(Newsfile Corp. - December 15, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) betwee...
NEW YORK, Dec. 15, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: ...
New York, New York--(Newsfile Corp. - December 14, 2020) - Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the ...
NEW YORK, Dec. 13, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NAS...
NEW YORK, Dec. 12, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between Novemb...
Investors need to pay close attention to Celsion (CLSN) stock based on the movements in the options market lately.
NEW YORK, Dec. 10, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 20...
NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Celsion Corporation (NASDAQ: ...
NEW YORK, Dec. 7, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 an...
NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation (“Celsion” or the “Company”) (NAS...
New York, New York--(Newsfile Corp. - December 5, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between...
NEW YORK, Dec. 03, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 20...
NEW YORK, Dec. 3, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against certain officers of Celsion Corporation ("Celsion" or the "Company") (NASDAQ: ...
New York, New York--(Newsfile Corp. - November 27, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) betwee...
The Insider Monkey team has completed processing the quarterly 13F filings for the September quarter submitted by the hedge funds and other money managers included in our extensive database. M...
NEW YORK, Nov. 26, 2020 (GLOBE NEWSWIRE) -- Zhang Investor Law announces a class action lawsuit on behalf of shareholders who bought shares of Celsion Corporation (NASDAQ: CLSN) between Novemb...
NEW YORK, Nov. 25, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 20...
New York, New York--(Newsfile Corp. - November 18, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between...
Celsion Corporation's (CLSN) CEO Michael Tardugno on Q3 2020 Results - Earnings Call Transcript
Shares of Celsion (NASDAQ:CLSN) remained unaffected after the company reported Q3 results. Quarterly Results Earnings per share increased 32.00% over the past year to ($0.17), which missed the...
Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer
NEW YORK--(BUSINESS WIRE)--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation ("Celsion" or "the Company") (NASDAQ:...
NEW YORK, Nov. 9, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Celsion Corporation (NASDAQ: CLSN) between November 2, 2015 an...
LAWRENCEVILLE, N.J., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss financial results for the thir...
New York, New York--(Newsfile Corp. - November 4, 2020) - Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the secur...
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Celsion Co...
LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--SHAREHOLDER ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation.
NEW YORK, Nov. 3, 2020 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against of Celsion Corporation (...
LOS ANGELES--(BUSINESS WIRE)---- $CLSN #CLSN--SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Celsion Corporation.
About CLSN
Celsion Corporation, an integrated development clinical stage oncology drug company, focuses on the development and commercialization of directed chemotherapies, DNA-mediated immunotherapy, and RNA-based therapies for the treatment of cancer. Its lead product candidate is ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trial for treating primary liver cancer. The company is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation ... [Read more...]
| Industry Biotechnology | IPO Date Mar 5, 1985 |
| CEO Michael Tardugno | Employees 29 |
| Stock Exchange NASDAQ | Ticker Symbol CLSN |
Financial Performance
In 2019, Celsion's revenue was $500,000, a change of 0.00% compared to the previous year's $500,000. Losses were -$16.85 million, 41.8% more than in 2018.
Analyst Forecasts
According to one analyst, the rating for Celsion stock is "Strong Buy" and the 12-month stock price forecast is 4.50.